Details for: SIMPONI
Company: JANSSEN INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02417472 | SIMPONI I.V. | GOLIMUMAB | 50 MG / 4.0 ML | SOLUTION | INTRAVENOUS |
| 02324776 | SIMPONI | GOLIMUMAB | 50 MG / 0.5 ML | SOLUTION | SUBCUTANEOUS |
| 02324784 | SIMPONI | GOLIMUMAB | 50 MG / 0.5 ML | SOLUTION | SUBCUTANEOUS |
| 02413175 | SIMPONI | GOLIMUMAB | 100 MG / 1.0 ML | SOLUTION | SUBCUTANEOUS |
| 02413183 | SIMPONI | GOLIMUMAB | 100 MG / 1.0 ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Summary Safety Review - Tumour Necrosis Factor (TNF) alpha blockers (SIMPONI and CIMZIA) - Assessing the Potential Risk of Liver Inflammation (Autoimmune Hepatitis)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Regulatory Decision Summary
Summary Safety Review - Tumour Necrosis Factor (TNF) alpha blockers (SIMPONI and CIMZIA) - Assessing the Potential Risk of Liver Inflammation (Autoimmune Hepatitis)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.